Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada

Documenti analoghi

• A Global Cross‐Sectional Database Study of Low Dose FVIII SHL Prophylaxis in Haemophilia A
  di: Dagmar M. Hajducek, et al.
  Pubblicazione: (2025)
• Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A
  di: Jens Müller, et al.
  Pubblicazione: (2024)
• Evaluation of the Burden of Bone Fractures in People Living With Haemophilia: A Registry‐Based Matched Cohort Study
  di: Federico Germini, et al.
  Pubblicazione: (2026)
• Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients
  di: Dagmar M. Hajducek, et al.
  Pubblicazione: (2024)
• Exploring the Impact of Laboratory Reagents on Pharmacokinetic Profiling
  di: Pierre Chelle, et al.
  Pubblicazione: (2025)